All News

New methods allow the antiseizure treatment to be crushed and mixed with water for oral suspension or for use through a nasogastric tube.

Treatment was initially approved in 2017 for the same indication in children aged 12 and up.

Joint venture aims to implement Invenra’s B-Body bispecific antibody platform to enhance Astellas' research and development efforts.

Decree comes amid the FDA’s 2021 inspection of Philips’ Murrysville facility and the subsequent voluntary recall of its sleep and respiratory care devices.

The vaccine is already approved for older adults.

The move is part of Synaptogenix’s partnership with Cannasoul.

A Harvard Business School Healthcare Alumni Association Q&A with Louis Kassa, CEO of the Pennsylvania Biotechnology Center.

The latest news for pharma industry insiders.

The pharmacy will now operate as Saveway Compounding Pharmacy, a Myonex company.

A combination of data from the EMERGENT-4 trial and pooled data from the EMERGENT program showed the promise of KarXT (xanomeline-trospium) in providing symptom improvement for people with schizophrenia.

These expansions include a new product, along with improvements to existing products.

The latest news for pharma industry insiders.

Dovato is the first oral, two-drug, single-tablet regimen approved for patients 12 years of age and older who are living with HIV-1.

According to the letter, the FDA believes that the investigational apomorphine infusion device is not ready for approval in its current form.

PIONEER AF-PCI exploratory trial found that elderly patients experienced a lower rate of clinically significant bleeding after 12 months of treatment with Xarelto (rivaroxaban).

The approval of AstraZeneca’s and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for adults with unresectable or metastatic HER2-positive solid tumors adds to the drug's approved indications in breast cancer, non-small cell lung cancer, and gastroesophageal junction adenocarcinoma.

The latest news for pharma industry insiders.

The deal, which is worth approximately $13.1 billion, is part of J&J MedTech's goal to expand into high-growth markets.

Decision to discontinue marketing authorizations for Relyvrio/Albrioza comes as a result of topline results from the Phase III PHOENIX trial in patients with amyotrophic lateral sclerosis.

Abecma was found to triple progression-free survival compared to standard regimens with a 51% decline in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma who were previously administered two or more lines of therapy.

FDA’s program will provide guidance to the development of the company’s Delphi-MD technology.

The technology will reportedly improve consumer engagement.

The vaccine can reportedly prevent infection from a fungal source that impacts both people and dogs.

The latest news for pharma industry insiders.

Early results have demonstrated that mRNA-3927 has led to a 70% reduction in the relative risk for metabolic decompensation events in patients with propionic acidemia.

Agreement comes as Teva aims to strengthen its biosimilar portfolio as part of its "Pivot to Growth" strategy.

The two programs will be offered to students and CVS interns.

Otsuka and Click Therapeutics co-developed Rejoyn, a digital therapeutic for MDD.